Prospects for a dengue virus vaccine

Stephen S Whitehead1, Joseph E Blaney, Anna P Durbin

  • 1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. swhitehead@niaid.nih.gov

Summary

Severe dengue is increasing globally, especially in children. Developing a cost-effective tetravalent dengue vaccine effective against all serotypes and providing long-term protection is a critical public health priority.